The CRA has confirmed that there will be $7,000 more in TFSA (Tax-Free Savings Account) contribution room in 2026. If you haven’t used it yet, now is the time to do so. Putting money in a savings account that earns 3% is not the best way to build long-term wealth in a TFSA. Instead, buy good growth stocks and let compounding do the work, tax-free.
The TFSA Contribution Has Gone Up By $7,000
The TFSA was created in 2009 and is now the most flexible investment account for Canadians. The CRA sets a new limit on contributions every year. The limit for 2026 is $7,000, which is the same as it was for 2024 and 2025.
If you haven’t contributed before, your total room in 2026 could be as much as $109,000, depending on how old you are and where you’ve lived.
Are You Sick of Trying to Guess Which Stocks to Buy?
It can be a good idea to listen when our analysts have a stock tip. Stock Advisor Canada’s total average return is 87%, which is much better than the S&P/TSX Composite Index’s 76%.
They told us what they think are five stocks that investors should buy right now. You can get them when you sign up for Stock Advisor Canada.
Why the TFSA Is So Valuable for Growth Stocks
Here’s why that matters. There is no tax on any money you make in a TFSA, whether it’s from capital gains, dividends, or interest. For all time. If you have high-growth assets, the difference between a taxable account and a TFSA can be tens of thousands of dollars over the course of 20 or 30 years.
Why You Should Put This Small-Cap Stock in Your TFSA
People don’t know much about AbCellera. But this type of business usually pays off for investors who find it early.
AbCellera, which was founded in 2012 and is based in Vancouver, has spent more than a decade and about $1 billion building a complete platform for finding, developing, and now making antibody-based medicines.
At the TD Cowen Healthcare Conference in March 2026, Martin Hogan, the company’s Senior Director of Strategic Finance and Investor Relations, said that what started as a drug discovery service business has grown into something much more valuable: a fully integrated biotech with its own clinical pipeline.
Strong Balance Sheet
At the end of 2025, AbCellera had about US$700 million in cash, cash equivalents, and promised government funding. It uses about $120 million to $130 million in cash each year to run its business.
That gives ABCL more than three years to run at full speed without having to cut programs or give up shareholders. The company also built its own clinical-grade manufacturing facility in Vancouver, which is not something that many biotech companies of this size do.
Hogan mentioned a less obvious benefit: AbCellera gets two to four more years of effective patent protection on each drug because the sequences stay in-house instead of being sent to a contract manufacturer.
Investment Considerations
If you’re a conservative investor, you shouldn’t buy AbCellera stock. It’s a biotech that is in the clinical stage. The Phase II readout in Q3 will either confirm or greatly hurt the thesis.
But AbCellera is a great investment for TFSA investors who are willing to take on more risk for more reward and have a longer time frame.
It’s a Canadian company with a lot of money, a unique platform, a clear short-term reason to buy, and a pipeline that should grow for years.
